biostudies-literatureLarsen VBreast Cancer Research FoundationSusan G. Komen FoundationNCI NIH HHSNational Institutes of HealthNIH225-235.e2https://www.ebi.ac.uk/biostudies/studies/S-EPMC6667288biostudies-literatureUnknown19(4)<h4>Introduction</h4>GATA3 is a critical transcription factor in maintaining the differentiated state of luminal mammary epithelial cells. We sought to determine the prognostic and predictive roles of GATA3 genotypes for breast cancer.<h4>Patients and methods</h4>Twelve single nucleotide polymorphisms (SNPs) were genotyped in 2 breast cancer cohorts, including the SWOG S8897 trial where patients were treated with adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5-fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5-fluorouracil]) or untreated, and the observational Pathways Study.<h4>Results</h4>In the S8897 trial, rs3802604 and rs568727 were associated with disease-free survival and overall survival in the treated group, regardless of chemotherapy regimen. The GG genotype ofClinical breast cancerGermline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.PMC6667288UG1 CA189821U10 CA180819P30 CA016056UG1 CA189830R01 CA105274U01 CA195565U10 CA180801UG1 CA233160U10 CA180888U24 CA171524Ravdin PMRoh JMHortobagyi GNOsborne CKHutchins LFYao SKushi LHLiu SKwan MLYang JJYeh ITErgas IJBarlow WELarsen VAlbain KSHayes DFMartino SZhu QAmbrosone CBKadlubar SARae JMLyss APfalseGermline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.<h4>Introduction</h4>GATA3 is a critical transcription factor in maintaining the differentiated state of luminal mammary epithelial cells. We sought to determine the prognostic and predictive roles of GATA3 genotypes for breast cancer.<h4>Patients and methods</h4>Twelve single nucleotide polymorphisms (SNPs) were genotyped in 2 breast cancer cohorts, including the SWOG S8897 trial where patients were treated with adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5-fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5-fluorouracil]) or untreated, and the observational Pathways Study.<h4>Results</h4>In the S8897 trial, rs3802604 and rs568727 were associated with disease-free survival and overall survival in the treated group, regardless of chemotherapy regimen. The GG genotype of2019-01-01T00:00:00Z2019 Aug2026-04-29T17:45:51.417Z2020-09-11T07:22:16ZS-EPMC66672883092841310.1016/j.clbc.2019.02.010